Metronomic capecitabine combined with an aromatase inhibitor extends median progression-free survival to 20.9 months compared with 11.9 months for aromatase inhibitor alone in hormone receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback